Abstract
Conflicts of interest C.A.M. has received honoraria for speaking, organized educational events and conducted research for Galderma, PhotoCure and Phototherapeutics Ltd. Heard about the therapy reporting 99% lesion and 96% patient complete clearance rates for actinic keratoses (AKs)? Perhaps not, unless you have already read the BJD epub accepted articles section. These are the clearance rates achieved for immunocompetent patients with four to eight mild to moderate AK lesions on the face/scalp recruited to a randomized, multicentre, double‐blind, placebo‐controlled study of topical photodynamic therapy (PDT) published in this month’s BJD.1 A new, stable nanoemulsion formulation of 10% aminolaevulinic acid (ALA) was combined with illumination by one of two light sources, and the impressive clearance rates were achieved by only one of the sources, a narrowband red light‐emitting diode (LED) source. The protocol did permit a second treatment after 12 weeks and clearance rates are based on clinical assessment, only 12 weeks after last treatment. Nevertheless, these are impressive results and will stimulate fresh enthusiasm into re‐evaluating PDT for AK.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
